Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Solid performance @ BIEL
Professional presentation with strategic business model that is shareholder friendly not to mention a new way of re-writing pain with a patch rather than pills that have strong side-effects!
Added 100K shares during the call.
GLTA
Investor 100
GO Sheff- Got a question in with FDA question!
To hear from the FDA in August and cleared for the device to treat eye lid surgery and have marketed for 4 years..approval should not be a problem!
Nice composure Sheff and great questions!
Hope these guys do not grab you as a brand manager!
Investor 100
GO Sheff- Got a question in with FDA question!
To hear from the FDA in August and cleared for the device to treat eye lid surgery and have marketed for 4 years..approval should not be a problem!
Nice composure Sheff and great questions!
Hope these guys do not grab you as a brand manager!
Investor 100
Solid call thus far @ BIEL
My notes: CC on BIEL
1) 50K convertible debt reduction
2) Upcoming publication by year-end.
3) Testimony on the patch 10 point results spoken by female user!
4) International distribution- Western Europe- now going into Germany and Spain ( new regions) Canada 235 drug stores got presentation recently.
5) Asia partners conversation beginning - Korea - China.
6) Demand scientific studies- infection (?) demand up!
7) FDA filings 510 ( june 2009 ) FDA should be respond by 90 days so also file application ( surgical + heal + foot pain )
8) Back-Pain opportunity - PR coming -leap frog application for all muscular skeleton
9) Market size data: 3 brands - published report coming this week.
10) Market: Pain Relief- Billions
11) C-Section: 2006 data 1.34M performed in USA / 33% of births. 13.4M if secure 20% by BIEL
12) Cosmetics-Eyes-Nose,Breasts -2008 / 5M performs 20% would bring 66M
13) Pain: 50M woman monthly period pain 5% market opportunity would bring 80M per year.
14) Added all together is in the billions with few competitors.
15) 35 page report from independent analysis.
16) FDA panel: July 3,2009 - Issues /recommendations
17) New Patents in the works.
18) Financials: June 2008-900K - down today below $50K!!!
19) Convertible debt free in a few weeks.
20) No raising of cash is necessary .
21) Gross Margins: Moving up!
22) Expenses: Tight control measures in place!
23) No red ink: Smnll loss and profitable soon.
24) Export-Import Bank ( US govt ): BIEL getting help cost of capital is low- nice profit going forward!
25) Clinical studies: #1 goal--many are closing soon to get submission to FDA..leap frog concept.
26) Expand the brand in all markets- hired two brand managers!
Goal is to re-write pain medication!
27) Q/A session.
Sheff, I am impressed with this company and its future moving forward!
Investor 100
That is why I fired my broker :)
Broken orders, promises and losses.
Investor 100
LOL!
After the call you can fire him/her (LOL)
Investor 100
Ticker Tape Before CC @ BIEL
http://ih.advfn.com/p.php?pid=trades&cb=1248792972&symbol=BIEL
GLTA
Investor 100
Ticket Tape Before the CC @ BIEL
http://ih.advfn.com/p.php?pid=trades&cb=1248788232&symbol=BIEL&java_vm=sun&java_vm_ver=1.6.0_12
GLTA
Investor 100
Conference Call @ BIEL
To access the call, dial (888) 296-4217 five to ten minutes before the start time. You may be asked for passcode 4461002. There will be a replay of the call available for seven days, which can be accessed by dialing (888)203-1112 and entering passcode 4461002. Those seeking to access the call or recording from outside the U.S. should contract the Company for dial instructions.
Added 100K on the dip @ BIEL
Bought .065
Holding 200K into the CC this morning.
GLTA
Investor 100
LOD @ BIEL
Huge walk down now trading .064
GLTA
Investor 100
Morning Ticker Tape @ BIEL
http://ih.advfn.com/p.php?pid=trades&cb=1248788232&symbol=BIEL&java_vm=sun&java_vm_ver=1.6.0_12
Lots of activity before the CC this morning.
GLTA
Investor 100
Nice Boards Stat's Sheff!
http://investorshub.advfn.com/boards/top_boards.aspx
http://investorshub.advfn.com/boards/TopPersonMarks.aspx
Sitting very well among the top boards and personal marks!
And making $$ to boot!
Congrats to a solid board @ IHUB!
Investor 100
Insider Buying @ JAZZ
http://www.secform4.com/insider-trading/1232524.htm
Sheff, lots of insiders buying this stock ( indirect ).
Up today as well as AH
Investor 100
4Pm Ticker Tape @ BIEL
http://ih.advfn.com/p.php?pid=trades&cb=1248729740&symbol=BIEL
Lots of MOMO going into tomorrow CC
GLTA
Investor 100
Schedule 14A @ HEB
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6432254
GLTA
Investor 100
This Sums it up @ DPDW for 2009
Wish I could post a bunch of contracts but that is not the case so far in 2009 with five months to go..it will take a Deep Down effort to get this PPS up! ( IMO )
The best news is the most recent PR that could potentially prove a benefit given the activity in Brazil.
-------------------------------------------------------
In The Press
07/1/09 - Deep Down Expands Presence in Brazil
Deep Down, Inc., a global leader in offshore deepwater products and services for the oil and gas industry, today announced the engagement of Marcelo Lardosa as Business Development Officer.
05/14/09 - Deep Down Inc Announces First Quarter Results
Deep Down, Inc. announced today unaudited results for the first quarter ended March 31, 2009.
05/4/09 - Deep Down receives Deepwater Project Orders
Deep Down, Inc. today announced receipt of subsea service and technology orders for deepwater oil and gas fields in West Africa and the Gulf of Mexico (GOM).
04/20/09 - Deep Down S-1 Registration Declared Effective
Deep Down, Inc. today announced that its registration statement on Form S-1, registering approximately 57 million shares of its common stock,
04/3/09 - Deep Down Expands Sales Organization
Deep Down, Inc.today announced it has expanded its sales organization to support the substantial growth the Company is experiencing.
03/24/09 - Deep Down Awarded Patent for New Subsea J-Plate Design
Deep Down, Inc. today announced that it has been awarded a patent [number 7,467,662 B2] by the United States Patent and Trademark Office.
03/19/09 - Deep Down Reports 84.5% Increase in Revenue
Deep Down, Inc. today commented on its results of operations for the year ended December 31, 2008, reported on Form 10-K and filed on March 16, 2009 with the Securities and Exchange Commission.
02/27/09 - Deep Down Opens New Houston Corporate Headquarters
Deep Down, Inc. today announced it has opened new corporate headquarters in Northwest Houston, at 8827 W. Sam Houston Parkway, N., Suite 100, Houston, Texas 77040.
01/26/09 - Deep Down Expanding Buoyancy Facilities to Serve Growing Deepwater Market
Deep Down, Inc. today announced expansion plans of its buoyancy manufacturing facility and flotation testing services in response to recent orders and anticipated demand...
GLTA
Investor 100
4pm Ticker Tape @ BIEL
http://ih.advfn.com/p.php?pid=trades&cb=1248713990&symbol=BIEL
Lots of MOMO going into tomorrow!
Great pick Sheff and congrats to all that participated.
GLTA
Investor 100
HOD @ NSPH
$5.18
GLTA
Investor 100
Afternoon Tape @ BIEL
http://ih.advfn.com/p.php?pid=trades&cb=1248713990&symbol=BIEL
Took a dip to .074.
GLTA
Investor 100
Sold 100K shares @ Biel
Profit: $4,560.00 Entered: .0341 sold .077
Holding 100K til tomorrow.
Thanks SHEFF!
GLTA
Investor 100
Sold 100K shares @ BIEL
Profit $4300.00 Entered: .0314 sold .075
Holding 200K til the CC tomorrow.
Thank you Sheff!
GLTA
Investor 100
HOD @ BIEL
.074
Lots of MOMO
GLTA
Investor 100
I nominate fourkids!
Investor 100
Mid-Afternoon Trading Tape @ BIEL
http://ih.advfn.com/p.php?pid=trades&cb=1248702096&symbol=BIEL&java_vm=sun&java_vm_ver=1.6.0_12
GLTA
Investor 100
HOD @ HEB
$2.50
GL
Investor 100
Mid-Afternoon Tape @ BIEL
http://ih.advfn.com/p.php?pid=trades&cb=1248702096&symbol=BIEL&java_vm=sun&java_vm_ver=1.6.0_12
GLTA
Investor 100
Mid-Morning Tape @ BIEL
http://ih.advfn.com/p.php?pid=trades&cb=1248702096&symbol=BIEL&java_vm=sun&java_vm_ver=1.6.0_12
Today's trading range: 0.0652 - 0.0740
GLTA
Investor 100
Solid Profit Sheff.
Investor 100
Trading Tape @ Biel (10am)
http://ih.advfn.com/p.php?pid=trades&cb=1248702096&symbol=BIEL&java_vm=sun&java_vm_ver=1.6.0_12
GLTA
Investor 100
Bought a few more on the dip @ BIEL
Purchased 50K @ .068
Me, 300K average .045
GLTA
Investor 100
HOD @ BIEL
Out early this morning with strong MOMO
.074
Investor 100
SEC Form - 4 (NSPH)
http://www.secform4.com/insider-trading/1105184.htm
Lots of buying in the recent past Sheff.
Investor 100
Form 8-K for BIODELIVERY SCIENCES INTERNATIONAL INC
24-Jul-2009
Other Events
Item 8.01. Other Information.
On July 23, 2009, BioDelivery Sciences International, Inc. (the "Company") held its 2009 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, a majority of the Company's shares of common stock represented at the Annual Meeting and voting on each proposal voted to approve the following proposals:
1. to amend the Company's Amended and Restated 2001 Incentive Plan to increase the number of shares of Company common stock reserved for issuance under such plan from 3,500,000 to 6,000,000;
2. to elect Francis E. O'Donnell, Jr., M.D. as a Class I director to serve for a three-year term that expires at the 2012 Annual Meeting of Stockholders, or until his successor has been duly elected and qualified; and
3. to ratify the appointment by the Audit Committee of the Company's Board of Directors of Cherry, Bekaert & Holland, L.L.P as the Company's independent auditors for the fiscal year ending December 31, 2009.
This Current Report on Form 8-K and the exhibits hereto and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation: (i) actual sales results and royalty or milestone payments, if any,
(ii) the application and availability of corporate funds and the Company's need for future funds, or (iii) the timing for completion, and results of, scheduled or additional clinical trials and the FDA's or other regulatory review and/or approval and commercial launch of the Company's formulations and products and regulatory filings related to the same, may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).
http://biz.yahoo.com/e/090724/bdsi8-k.html
Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
- Management to discuss second quarter financial result.
LAVAL, QC, July 27 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS - News; NASDAQ: DDSS - News) today announced that it will host a conference call on Friday, August 7, 2009 at 8:30 a.m. (ET) to discuss its second quarter 2009 financial results. Labopharm will report its second quarter 2009 financial results via news release at approximately 7:00 a.m. the same day.
To access the conference call by telephone, dial 416-644-3427 or 1-800-588-4490. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, August 14, 2009 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21311012 followed by the number sign.
A live audio webcast of the conference call will be available at www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is now available in 17 countries around the world, including the U.S., Canada, major European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit
www.labopharm.com.
http://finance.yahoo.com/news/Labopharm-to-host-conference-prnews-675648993.html?x=0&.v=53
FINANCIALS ARE OUT HERE IS LINK.....
Also, take a look a the DD posts by Sheff who is astute regarding this industry!
http://pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=22637
TSPT Participates Healthcare Conference
Sheff, (TSPT) could awaken with its upcoming healthcare conference conferenece in New York during the first week of August.
RICHMOND, Calif., July 22 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT - News), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to present at the BMO Capital Markets Healthcare Conference in New York City on Wednesday, August 5, 2009 at 4:00 p.m., Eastern Time.
An audio webcast of the presentation will be available at www.transcept.com. The audio replay of the presentation will be available at the same location through September 4, 2009.
About Transcept Pharmaceuticals (TSPT)
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. Its lead product candidate, Intermezzo® (zolpidem tartrate sublingual tablet), has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. For further information, please visit the company's website at www.transcept.com.
About Intermezzo®
Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. Intermezzo® is a sublingual low dose formulation of zolpidem, the active agent most commonly prescribed in the United States for the treatment of insomnia. Intermezzo® uses approximately one-quarter to one-third of the dose of active drug contained in currently marketed zolpidem-based sleep aids, in a formulation designed to promote rapid sublingual absorption. As compared to placebo, two Phase 3 clinical studies of Intermezzo® showed a statistically significant reduction in the time it took patients to return to sleep after a middle of the night awakening, and there were no significant residual effects upon awakening four hours after dosing. Transcept believes that Intermezzo®, by combining the reduced zolpidem dose with administration only on those nights when a middle of the night awakening actually occurs, has the potential to reduce unnecessary sedative-hypnotic exposure.
The U.S. Food and Drug Administration (FDA) has established October 30, 2009 as its target date under PDUFA (the Prescription Drug User Fee Act) to take action on its review of the New Drug Application (NDA) for Intermezzo®. Transcept is actively pursuing patents to protect Intermezzo® in the United States and key non-U.S. markets, and, as part of the NDA submission, has requested that the FDA grant three years of Hatch-Waxman marketing exclusivity to Intermezzo®.
About Middle of the Night Awakenings
Waking up during the night is the most frequent insomnia symptom reported in the general population. Based on a recently published epidemiological study of nearly 9,000 individuals, the Stanford Sleep Epidemiology Research Center has estimated that about one-third of adults in the United States experience middle of the night awakenings at least three times each week. The study concluded that more than 90 percent of those subjects who experienced middle of the night awakenings reported that this insomnia symptom persisted for at least six months, and approximately 11 percent had consulted a physician in regard to this sleep condition. In the Stanford study, fewer than 25 percent of those experiencing middle of the night awakenings reported difficulty going to sleep at bedtime. According to IMS Health, the overall U.S. market for prescription sleep aids was approximately $4.0 billion in 2008.
Forward Looking Statements
This press release contains forward looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the potential for Intermezzo® to be the first prescription sleep aid specifically approved by the FDA for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep and the potential for the use of Intermezzo® to reduce unnecessary sedative-hypnotic exposure in the insomnia patient population. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, whether FDA determines that the Intermezzo® NDA is sufficient to approve Intermezzo® for its intended indication and any delays in, and the final form of, any FDA approval of Intermezzo®; the ability of Transcept to commercialize Intermezzo® effectively, if approved; physician or patient reluctance to use Intermezzo®, if approved; potential alternative therapies; obtaining and maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; obtaining and maintaining Hatch-Waxman exclusivity for Intermezzo® and other difficulties or delays in, clinical development, market acceptance and commercialization of Intermezzo®.
http://finance.yahoo.com/news/Transcept-Pharmaceuticals-to-prnews-4202996539.html?x=0&.v=1
Pennystockgurus @ BIEL
Sheff, this stock is receiving some tremendous coverage throughout various boards and with any positive updates on Tuesday this will take it to new levels (IMO)
Thursday, July 23, 2009
BIEL - More Gains Today
BIEL continued its bullish rampage today, following the big board surge, and climbed to an all-time high of $.0665 well off it low of $.0011 in Early May. The action today could have very well been the top of the over all move in the stock.
Below is the news from Wednesday:
BioElectronics to Hold Conference Call to Discuss Clinical Data Results and Status of FDA Filings
Dr. David G. Genecov to Present Results of a Clinical Study and Management Team to Provide Update on Corporate Activities, Other Clinical Studies, Distribution and FDA Filings
FREDERICK, MD, Jul 22, 2009 (MARKETWIRE via COMTEX) -- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced a conference call will be held at 11AM (EDT), Tuesday, July 28th to discuss the results of a clinical study recently completed under the direction of David G. Genecov, M.D. FACS FAAP and Joel Brook, DPM, MS, FACFAS. The management team will also provide its stakeholders with an update on corporate activities and information on the status of FDA filings.
"We are very excited about the completion of this important study and we look forward to discussing the results. We thank Dr. Genecov and Dr. Brook and the many other physician primary investigators who are working diligently to determine the efficacy and safety of our patented, portable PEMF technology," commented Andrew Whelan, CEO of BioElectronics. "On our last call we had over 550 investors attempt to access the call, which overwhelmed the capacity of the conference bridge. We have ensured that all who attempt to access next week's call will be able to hear Dr. Genecov and the management team provide the latest information on the exciting developments at our company. We will also be available to answer your questions after the formal presentations have been completed."
To access the call, dial (888) 296-4217 five to ten minutes before the start time. You may be asked for passcode 4461002. There will be a replay of the call available for seven days, which can be accessed by dialing (888)203-1112 and entering passcode 4461002. Those seeking to access the call or recording from outside the U.S. should contract the Company for dial instructions.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch(R) Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com) and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
Read more about Dr. Genecov at the following link: http://www.genecovplasticsurgery.com/images/CV_genecov.pdf
Read more about Dr. Brook at the flowing link: http://www.dallaspodiatryworks.com/about.html
For media enquiries, please contact:
Joe Noel
(925) 922-2560
http://pennystockgurus.blogspot.com/2009/07/biel-more-gains-today.html
Nanotechnology Report @ BIEL
Despite a report dated Nov 2008 it is clear back then that BioEctectronics Corporation offered a product that produced positive results to the community.
----------------------------------------------------
BioElectronics Corp. (OTCPK:BIEL), the maker of ActiPatch™, the drug free anti-inflammatory patch, with an embedded battery operated microchip delivering continuous pulse therapy that revolutionizes the way people heal, today announced that Emerging Growth Research, LLP has issued a Buy recommendation on the company's shares through a new research report on the company. The report, which places a12-month target price of $0.20 on the company's shares, outlines the research firm's belief that the Company's sales are aggressively ramping and that positive clinical data is expected over the next few months. The report can be viewed online at www.wallstreetreportonline.com.
Andrew Whelan, CEO and President of BioElectronics Corp. commented, "We are very pleased to have received such a positive rating in this research report. The management team at BioElectronics is very excited about the positive developments taking place at the company, especially relating to our international distribution. Over the past few months shipments to our international distributors have substantially increased. We believe this is a trend that is likely to continue allowing us to report record revenue levels over the coming quarters. We continue to believe the future is very bright for our company and its shareholders."
Posted November 24th, 2008
Nanotechnology Report @ BIEL
Despite a report dated Nov 2008 it is clear back then that BioEctectronics Corporation offered a product that produced positive results to the community.
----------------------------------------------------
BioElectronics Corp. (OTCPK:BIEL), the maker of ActiPatch™, the drug free anti-inflammatory patch, with an embedded battery operated microchip delivering continuous pulse therapy that revolutionizes the way people heal, today announced that Emerging Growth Research, LLP has issued a Buy recommendation on the company's shares through a new research report on the company. The report, which places a12-month target price of $0.20 on the company's shares, outlines the research firm's belief that the Company's sales are aggressively ramping and that positive clinical data is expected over the next few months. The report can be viewed online at www.wallstreetreportonline.com.
Andrew Whelan, CEO and President of BioElectronics Corp. commented, "We are very pleased to have received such a positive rating in this research report. The management team at BioElectronics is very excited about the positive developments taking place at the company, especially relating to our international distribution. Over the past few months shipments to our international distributors have substantially increased. We believe this is a trend that is likely to continue allowing us to report record revenue levels over the coming quarters. We continue to believe the future is very bright for our company and its shareholders."
Posted November 24th, 2008
http://www.azonano.com/news.asp?NewsID=8856